GlassScriptPhysician profile
Talal Aboud
NPI 1487018701
$3,656.79
in general payments reported to CMS, 2019-2025
37 companies · $1,088 in 2025
The $1,088 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $125 · 2021: $210 · 2022: $522 · 2023: $736 · 2024: $976 · 2025: $1,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,800.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,800.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $617.18 | 2021-2025 | Ubrelvy, Qulipta |
| Ucb, INC. | $309.96 | 2022-2025 | Briviact, Rystiggo, Fintepla |
| Emd Serono, INC. | $216.05 | 2024 | |
| Pfizer INC. | $184.91 | 2023-2025 | |
| Horizon Therapeutics Plc | $176.47 | 2022-2023 | Uplizna |
| Medtronic, INC. | $170.91 | 2021 | |
| Alexion Pharmaceuticals, INC. | $164.65 | 2020-2024 | Ultomiris |
| Neurelis, INC. | $161.49 | 2023-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $131.16 | 2022-2025 | |
| Lilly USA, LLC | $125.28 | 2022-2024 | Amyvid, Emgality, Reyvow |
| Eisai INC. | $122.61 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $109.83 | 2024-2025 | |
| Amgen INC. | $92.18 | 2021-2024 | Uplizna |
| Takeda Pharmaceuticals U.S.A., INC. | $84.29 | 2023-2025 | Hyqvia, Gammagard |
| Octapharma USA, INC. | $83.99 | 2023-2024 | Panzyga |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $81.06 | 2024-2025 | Vyvgart Hytrulo |
| Csl Behring | $78.13 | 2022-2023 | Hizentra |
| Astrazeneca Pharmaceuticals LP | $75.14 | 2022 | |
| Lundbeck LLC | $59.11 | 2024-2025 | Rexulti |
| Sk Life Science, INC. | $57.77 | 2023-2024 | |
| Genzyme Corporation | $53.88 | 2022 | |
| Acadia Pharmaceuticals INC | $52.84 | 2025 | Nuplazid |
| Janssen Pharmaceuticals, INC | $41.76 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $41.68 | 2025 | Rexulti |
| Mdd US Operations, LLC | $37.68 | 2024-2025 | Gocovri, Qelbree |
| Alnylam Pharmaceuticals INC. | $36.35 | 2024 | Amvuttra |
| Vertex Pharmaceuticals Incorporated | $34.39 | 2025 | |
| Kyowa Kirin, INC. | $34.31 | 2023 | Nourianz |
| Springworks Therapeutics, INC. | $33.06 | 2025 | Gomekli |
| Globus Medical, INC. | $32.96 | 2025 | Senza |
| Ge Healthcare | $27.85 | 2024 | |
| Merz Pharmaceuticals, LLC | $24.99 | 2022 | |
| Tanabe Pharma America, INC. | $23.34 | 2023 | |
| Amneal Pharmaceuticals LLC | $22.16 | 2024 | Rytary |
| Banner Life Sciences, LLC | $19.54 | 2022 | |
| Biogen, INC. | $19.39 | 2025 | Leqembi |
| Boston Scientific Corporation | $18.44 | 2024 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talal Aboud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.